Comparative efficacy of rivaroxaban and warfarin to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation in a real world setting.

Trial Profile

Comparative efficacy of rivaroxaban and warfarin to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation in a real world setting.

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Aug 2014

At a glance

  • Drugs Rivaroxaban (Primary) ; Warfarin
  • Indications Atrial fibrillation; Venous thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Janssen
  • Most Recent Events

    • 09 Aug 2014 New trial record
    • 04 Jun 2014 Results presented at the 19th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top